Evidence map›Paper›PMID 39854226›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Co-option of mitochondrial nucleic acid-sensing pathways by HSV-1 UL12.5 for reactivation from latent infection.

Patryk A Krakowiak, Matthew E Flores, Sean R Cuddy, Abigail L Whitford, Sara A Dochnal, Aleksandra Babnis, Tsuyoshi Miyake, Marco Tigano, Daniel A Engel, Anna R Cliffe

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Patryk A Krakowiak *Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.ORCID 0000-0002-5120-9811
Matthew E Flores *Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Sean R Cuddy *Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Abigail L WhitfordDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Sara A DochnalDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Aleksandra BabnisDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Tsuyoshi MiyakeDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Marco TiganoDepartment of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA 19107.
Daniel A EngelDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
Anna R CliffeDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.ORCID 0000-0003-1136-5171

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
TRAINING IN CELL AND MOLECULAR BIOLOGYT32GM008136 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI STUKENBERG, P. TODD · 1985 to 2020
$8.5M
From mtDNA stress to cellular immunity: Triggers, Mechanisms and EffectorsR35GM147191 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI Marco Tigano · 2022 to 2026
$2.2M
Investigating the impact and dynamic of mitochondrial common deletion in somatic cellsR01AG085782 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI Agnel Sfeir · 2023 to 2026
$2.2M
Role for UL12.5 and nucleic acid sensing in Phase I HSV reactivationR21AI171544 · NIAID · UNIVERSITY OF VIRGINIA · PI CLIFFE, ANNA RUTH · 2024 to 2025
$430k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI171544HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI00704HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM008136HHS | NIH | National Institute on Aging (NIA) R01AG085782NIAID NIH HHS R21 AI171544NIAID NIH HHS T32 AI007046NIA NIH HHS R01 AG085782NIGMS NIH HHS R35 GM147191NIGMS NIH HHS T32 GM008136The Owens Family Foundation 0000
6 · The paper itself

Abstract

Although viruses subvert innate immune pathways for their replication, there is evidence they can also co-opt antiviral responses for their benefit. The ubiquitous human pathogen, Herpes simplex virus-1 (HSV-1), encodes a protein (UL12.5) that induces the release of mitochondrial nucleic acid into the cytosol, which activates immune-sensing pathways and reduces productive replication in nonneuronal cells. HSV-1 establishes latency in neurons and can reactivate to cause disease. We found that UL12.5 is required for HSV-1 reactivation in neurons and acts to directly promote viral lytic gene expression during initial exit from latency. Further, the direct activation of innate immune-sensing pathways triggered HSV-1 reactivation and compensated for a lack of UL12.5. Finally, we found that the induction of HSV-1 lytic genes during reactivation required intact RNA- and DNA-sensing pathways, demonstrating that HSV-1 can respond to and active antiviral nucleic acid-sensing pathways to reactivate from a latent infection.

Indexed as

DNA, MitochondrialHerpes SimplexHerpesvirus 1, HumanLatent InfectionMitochondriaViral ProteinsVirus ActivationVirus LatencyAnimalsChlorocebus aethiopsGene Expression Regulation, ViralHumansImmunity, InnateNeuronsVero CellsVirus ReplicationDNA, MitochondrialViral Proteinsherpes simplex virusmitochondrial DNAreactivationSTINGUL12.5

Identifiers

PMID39854226
PMCPMC11789124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.